GLP1R and obesity disorder: Tirzepatide is a once weekly, single molecule dual glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) receptor agonist approved in adults for the treatment of T2D, obesity, and (in the US) moderate to severe obstructive sleep apnea in patients with obesity.